yingweiwo

Bupivacaine HCl (HSDB 7790)

Alias:
Cat No.:V1642 Purity: ≥98%
Bupivacaine HCl (AH250; HSDB7790; SKY0402; AH-250;Win-11318;HSDB-7790;SKY-0402; Marcaine),the hydrochloride salt ofBupivacaine, is a potent inhibitor of cAMP production that alsobinds to the intracellular portion of voltage-gated sodium channels and blocks sodium influx into nerve cells.
Bupivacaine HCl (HSDB 7790)
Bupivacaine HCl (HSDB 7790) Chemical Structure CAS No.: 18010-40-7
Product category: Sodium Channel
This product is for research use only, not for human use. We do not sell to patients.
Size Price Stock Qty
500mg
1g
5g
Other Sizes

Other Forms of Bupivacaine HCl (HSDB 7790):

  • Levobupivacaine-d9 hydrochloride
  • Bupivacaine-d9 (Bupivacaine-d9)
  • Bupivacaine hydrochloride monohydrate
  • Bupivacaine (SKY 0402)
Official Supplier of:
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Top Publications Citing lnvivochem Products
Purity & Quality Control Documentation

Purity: ≥98%

Product Description

Bupivacaine HCl (AH250; HSDB7790; SKY0402; AH-250; Win-11318; HSDB-7790; SKY-0402; Marcaine), the hydrochloride salt of Bupivacaine, is a potent inhibitor of cAMP production that also binds to the intracellular portion of voltage-gated sodium channels and blocks sodium influx into nerve cells. Bupivacaine is a medication used to freeze tissue in a specific area. It is administered by injecting it into the area, around a nerve that supplies the area, or into the spinal canal's epidural space. It is available mixed with a small amount of epinephrine to make it last longer. Bupivacaine binds to the intracellular portion of voltage-gated sodium channels and blocks sodium influx into nerve cells, which prevents depolarization.

Biological Activity I Assay Protocols (From Reference)
ln Vitro
In the spinal dorsal horn, an area intimately associated with central sensitization, bupivacaine hydrochloride blocks NMDA receptor-mediated synaptic transmission [1]. Bupivacaine hydrochloride shifts the half-maximal activation/deactivation membrane potential toward a slightly more negative membrane potential, which has an impact on the voltage dependence of channel activation and steady-state inactivation. The SCN5A channel has an IC50 of 2.18±0.16 μM for bupivacaine hydrochloride, which indicates a slight sensitivity in the inactive state[2]. With an IC50 of 16.5 μM, bupivacaine hydrochloride dose-dependently and reversibly inhibits SK2 channels [3].
ln Vivo
Bupivacaine does not only induce Ca2+ release from the sarcoplasmic reticulum (SR) in rats, but also inhibits Ca2+ uptake by the SR, which is mainly regulated by SR Ca2+ adenosine triphosphatase activity.
Cell Assay
Cell Viability Assay[3]
Cell Types: HEK 293 cells transfected with the SK2 gene (transfected cells were named SK2 cells)
Tested Concentrations: 10, 100, 1000 µM
Incubation Duration:
Experimental Results: The IC50 value was 16.5 µM.
Animal Protocol

Rats
ADME/Pharmacokinetics
Absorption, Distribution and Excretion
Systemic absorption of local anesthetics is dose- and concentration-dependendent on the total drug administered. Other factors that affect the rate of systemic absorption include the route of administration, blood flow at the administration site, and the presence or absence of epinephrine in the anesthetic solution. Bupivacaine formulated for instillation with [meloxicam] produced varied systemic measures following a single dose of varying strength. In patients undergoing bunionectomy, 60 mg of bupivacaine produced a Cmax of 54 ± 33 ng/mL, a median Tmax of 3 h, and an AUC∞ of 1718 ± 1211 ng\*h/mL. For a 300 mg dose used in herniorrhaphy, the corresponding values were 271 ± 147 ng/mL, 18 h, and 15,524 ± 8921 ng\*h/mL. Lastly, a 400 mg dose used in total knee arthroplasty produced values of 695 ± 411 ng/mL, 21 h, and 38,173 ± 29,400 ng\*h/mL.
Only 6% of bupivacaine is excreted unchanged in the urine.
After absorption into the blood, bupivacaine hydrochloride is more highly bound to plasma proteins than are any other local anesthetics; bupivacaine is reportedly 82-96% bound. Bupivacaine hydrochloride has the lowest degree of placental transmission of parenteral local anesthetics and may cause the least fetal depression.
Pregnant rats received an intravenous infusion of bupivacaine at a rate of 0.33 mg. kg-1. min-1 over a period of 15 min. The fetuses were delivered either at the end of infusion or at 2 or 4 hr after dosing. Maternal and fetal blood and tissue samples were obtained for the assays of bupivacaine and its metabolites using capillary gas chromatography-mass spectrometry. The elimination half-life of bupivacaine was 37.7 min. The major metabolite was 3'-hydroxybupivacaine. Bupivacaine and 3'-hydroxybupivacaine were present in all samples at the end of administration. The fetal to maternal concentration ratio of bupivacaine in plasma was 0.29, and in the placenta was 0.63. The amnion contained the highest bupivacaine concentration: threefold higher in the maternal and 11-fold higher than in the fetal plasma. At 4 hr after dosing, bupivacaine was no longer detectable in any maternal and fetal samples, whereas 3'-hydroxybupivacaine was still present in all tissues except the fetal plasma and heart. These data indicate that a considerable amount of bupivacaine is taken up by both sides of the placenta, as well as the amnion and myometrium. 3'-Hydroxybupivacaine was present in all tissues except the fetal plasma and heart samples, even after the parent compound became no longer detectable.
After injection of Bupivacaine Hydrochloride for caudal, epidural, or peripheral nerve block in man, peak levels of bupivacaine in the blood are reached in 30 to 45 minutes, followed by a decline to insignificant levels during the next three to six hours.
Pharmacokinetic studies on the plasma profile of Bupivacaine Hydrochloride after direct intravenous injection suggest a three-compartment open model. The first compartment is represented by the rapid intravascular distribution of the drug. The second compartment represents the equilibration of the drug throughout the highly perfused organs such as the brain, myocardium, lungs, kidneys, and liver. The third compartment represents an equilibration of the drug with poorly perfused tissues, such as muscle and fat. The elimination of drug from tissue distribution depends largely upon the ability of binding sites in the circulation to carry it to the liver where it is metabolized.
For more Absorption, Distribution and Excretion (Complete) data for Bupivacaine (6 total), please visit the HSDB record page.
Metabolism / Metabolites
Amide-type local anesthetics such as bupivacaine are metabolized primarily in the liver via conjugation with glucuronic acid. The major metabolite of bupivacaine is 2,6-pipecoloxylidine, which is mainly catalyzed via cytochrome P450 3A4.
Pregnant rats received an intravenous infusion of bupivacaine at a rate of 0.33 mg. kg-1. min-1 over a period of 15 min. The fetuses were delivered either at the end of infusion or at 2 or 4 hr after dosing. Maternal and fetal blood and tissue samples were obtained for the assays of bupivacaine and its metabolites using capillary gas chromatography-mass spectrometry. The elimination half-life of bupivacaine was 37.7 min. The major metabolite was 3'-hydroxybupivacaine. Bupivacaine and 3'-hydroxybupivacaine were present in all samples at the end of administration. The fetal to maternal concentration ratio of bupivacaine in plasma was 0.29, and in the placenta was 0.63. The amnion contained the highest bupivacaine concentration: threefold higher in the maternal and 11-fold higher than in the fetal plasma. At 4 hr after dosing, bupivacaine was no longer detectable in any maternal and fetal samples, whereas 3'-hydroxybupivacaine was still present in all tissues except the fetal plasma and heart. These data indicate that a considerable amount of bupivacaine is taken up by both sides of the placenta, as well as the amnion and myometrium. 3'-Hydroxybupivacaine was present in all tissues except the fetal plasma and heart samples, even after the parent compound became no longer detectable.
Bupivacaine hydrochloride is principally metabolized to pipecolylxylidine (PPX) by N-dealkylation, probably in the liver. Bupivacaine is excreted in urine as small amounts of PPX, unchanged drug (5%), and other metabolites as yet unidentified.
Amide-type local anesthetics such as bupivacaine are metabolized primarily in the liver via conjugation with glucuronic acid. The major metabolite of bupivacaine is 2,6-pipecoloxylidine, which is mainly catalyzed via cytochrome P450 3A4.
Route of Elimination: Only 6% of bupivacaine is excreted unchanged in the urine.
Half Life: 2.7 hours in adults and 8.1 hours in neonates
Biological Half-Life
2.7 hours in adults and 8.1 hours in neonates. Bupivacaine applied together with [meloxicam] for postsurgical analgesia had a median half-life of 15-17 hours, depending on dose and application site.
Pregnant rats received an intravenous infusion of bupivacaine at a rate of 0.33 mg. kg-1. min-1 over a period of 15 min. The fetuses were delivered either at the end of infusion or at 2 or 4 hr after dosing. Maternal and fetal blood and tissue samples were obtained for the assays of bupivacaine and its metabolites using capillary gas chromatography-mass spectrometry. The elimination half-life of bupivacaine was 37.7 min.
The elimination half-life of bupivacaine hydrochloride is 1.5-5.5 hours in adults and 8.1 hours in neonates.
Toxicity/Toxicokinetics
Toxicity Summary
Bupivacaine is a cholinesterase or acetylcholinesterase (AChE) inhibitor. A cholinesterase inhibitor (or 'anticholinesterase') suppresses the action of acetylcholinesterase. Because of its essential function, chemicals that interfere with the action of acetylcholinesterase are potent neurotoxins, causing excessive salivation and eye-watering in low doses, followed by muscle spasms and ultimately death. Nerve gases and many substances used in insecticides have been shown to act by binding a serine in the active site of acetylcholine esterase, inhibiting the enzyme completely. Acetylcholine esterase breaks down the neurotransmitter acetylcholine, which is released at nerve and muscle junctions, in order to allow the muscle or organ to relax. The result of acetylcholine esterase inhibition is that acetylcholine builds up and continues to act so that any nerve impulses are continually transmitted and muscle contractions do not stop. Among the most common acetylcholinesterase inhibitors are phosphorus-based compounds, which are designed to bind to the active site of the enzyme. The structural requirements are a phosphorus atom bearing two lipophilic groups, a leaving group (such as a halide or thiocyanate), and a terminal oxygen.
Toxicity Data
The mean seizure dosage of bupivacaine in rhesus monkeys was found to be 4.4 mg/kg with mean arterial plasma concentration of 4.5 mcg/mL.
LD50: 6 to 8 mg/kg (intravenous, mice)
LD50: 38 to 54 mg/kg (subcutaneous, mice)
Interactions
Solutions of Bupivacaine Hydrochloride containing a vasoconstrictor, such as epinephrine, should be used with extreme caution in patients receiving monoamine oxidase inhibitors (MAOI) or antidepressants of the triptyline or imipramine types, because severe prolonged hypertension may result.
Bupivacaine Hydrochloride with epinephrine 1:200,000 or other vasopressors should not be used concomitantly with ergot-type oxytocic drugs, because a severe persistent hypertension may occur.
Non-Human Toxicity Values
LD50 Mouse sc 38-54 mg/kg
LD50 Mouse iv 6-8 mg/kg
References

[1]. Bupivacaine, levobupivacaine and ropivacaine: are they clinically different? Best Pract Res Clin Anaesthesiol. 2005 Jun;19(2):247-68.

[2]. Inhibition of gastric cancer by local anesthetic bupivacaine through multiple mechanisms independent of sodium channel blockade. Biomed Pharmacother. 2018 Jul;103:823-828.

Additional Infomation
Therapeutic Uses
Bupivacaine hydrochloride is used for infiltration anesthesia and for peripheral, sympathetic nerve, and epidural (including caudal) block anesthesia. A 0.75% solution of the drug in 8.25% dextrose is used for spinal anesthesia. Bupivacaine is not used for obstetric paracervical block or topical anesthesia. /Use Included in US product label/
Bupivacaine Hydrochloride is indicated for the production of local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures. Only the 0.25% and 0.5% concentrations are indicated for obstetrical anesthesia. /Use Included in US product label/
Drug Warnings
The 0.75% solution of bupivacaine hydrochloride is no longer recommended for obstetric anesthesia, since use of this concentration for epidural anesthesia in obstetric patients has been associated with cardiac arrest with difficult resuscitation or death. Cardiac arrest has occurred after seizures resulting from systemic toxicity, apparently following inadvertent intravascular injection.
Local anesthetics should only be employed by clinicians who are well versed in diagnosis and management of dose-related toxicity and other acute emergencies which might arise from the block to be employed, and then only after insuring the immediate availability of oxygen, other resuscitative drugs, cardiopulmonary resuscitative equipment, and the personnel resources needed for proper management of toxic reactions and related emergencies. delay in proper management of dose-related toxicity, under ventilation from any cause, and/or altered sensitivity may lead to the development of acidosis, cardiac arrest and, possibly, death. /Local anesthetics/
Pending accumulation of further data on the use of the drug in pediatric patients, bupivacaine hydrochloride solutions should not be used in children younger than 12 years of age and the solution for spinal anesthesia should not be used in children younger than 18 years of age.
Some commercially available formulations of bupivacaine hydrochloride contain sodium metabisulfite, a sulfite that may cause allergic-type reactions, including anaphylaxis and life-threatening or less severe asthmatic episodes, in certain susceptible individuals. The overall prevalence of sulfite sensitivity in the general population is unknown but probably low; such sensitivity appears to occur more frequently in asthmatic than in nonasthmatic individuals.
For more Drug Warnings (Complete) data for Bupivacaine (18 total), please visit the HSDB record page.
Pharmacodynamics
Bupivacaine is a widely used local anesthetic agent. Bupivacaine is often administered by spinal injection prior to total hip arthroplasty. It is also commonly injected into surgical wound sites to reduce pain for up to 20 hours after surgery. In comparison to other local anesthetics it has a long duration of action. It is also the most toxic to the heart when administered in large doses. This problem has led to the use of other long-acting local anaesthetics:ropivacaine and levobupivacaine. Levobupivacaine is a derivative, specifically an enantiomer, of bupivacaine. Systemic absorption of local anesthetics produces effects on the cardiovascular and central nervous systems. At blood concentrations achieved with therapeutic doses, changes in cardiac conduction, excitability, refractoriness, contractility, and peripheral vascular resistance are minimal. However, toxic blood concentrations depress cardiac conduction and excitability, which may lead to atrioventricular block, ventricular arrhythmias and to cardiac arrest, sometimes resulting in fatalities. In addition, myocardial contractility is depressed and peripheral vasodilation occurs, leading to decreased cardiac output and arterial blood pressure. Following systemic absorption, local anesthetics can produce central nervous system stimulation, depression or both.
These protocols are for reference only. InvivoChem does not independently validate these methods.
Physicochemical Properties
Molecular Formula
C18H28N2O.HCL
Molecular Weight
324.89
Exact Mass
324.196
CAS #
18010-40-7
Related CAS #
Bupivacaine;38396-39-3;Bupivacaine hydrochloride monohydrate;73360-54-0
PubChem CID
2474
Appearance
White to off-white solid powder
Boiling Point
423.4ºC at 760 mmHg
Melting Point
107.5 to 108ºC
Flash Point
209.9ºC
LogP
4.709
Hydrogen Bond Donor Count
1
Hydrogen Bond Acceptor Count
2
Rotatable Bond Count
5
Heavy Atom Count
21
Complexity
321
Defined Atom Stereocenter Count
0
InChi Key
SIEYLFHKZGLBNX-UHFFFAOYSA-N
InChi Code
InChI=1S/C18H28N2O.ClH/c1-4-5-12-20-13-7-6-11-16(20)18(21)19-17-14(2)9-8-10-15(17)3;/h8-10,16H,4-7,11-13H2,1-3H3,(H,19,21);1H
Chemical Name
1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide hydrochloride
Synonyms

Marcaine; AH-250; Win-11318; HSDB7790;SKY0402; AH 250; Win 11318;AH250;HSDB 7790; SKY 0402; HSDB-7790;SKY-0402; Win11318

HS Tariff Code
2934.99.9001
Storage

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light.
Shipping Condition
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
Solubility Data
Solubility (In Vitro)
DMSO: 65 mg/mL (200.1 mM)
Water: 23 mg/mL (70.8 mM)
Ethanol:65 mg/mL (200.1 mM)
Solubility (In Vivo)
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.69 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.

Solubility in Formulation 2: ≥ 2.5 mg/mL (7.69 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.

View More

Solubility in Formulation 3: 13 mg/mL (40.01 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication.


 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 3.0780 mL 15.3898 mL 30.7796 mL
5 mM 0.6156 mL 3.0780 mL 6.1559 mL
10 mM 0.3078 mL 1.5390 mL 3.0780 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.

Calculator

Molarity Calculator allows you to calculate the mass, volume, and/or concentration required for a solution, as detailed below:

  • Calculate the Mass of a compound required to prepare a solution of known volume and concentration
  • Calculate the Volume of solution required to dissolve a compound of known mass to a desired concentration
  • Calculate the Concentration of a solution resulting from a known mass of compound in a specific volume
An example of molarity calculation using the molarity calculator is shown below:
What is the mass of compound required to make a 10 mM stock solution in 5 ml of DMSO given that the molecular weight of the compound is 350.26 g/mol?
  • Enter 350.26 in the Molecular Weight (MW) box
  • Enter 10 in the Concentration box and choose the correct unit (mM)
  • Enter 5 in the Volume box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 17.513 mg appears in the Mass box. In a similar way, you may calculate the volume and concentration.

Dilution Calculator allows you to calculate how to dilute a stock solution of known concentrations. For example, you may Enter C1, C2 & V2 to calculate V1, as detailed below:

What volume of a given 10 mM stock solution is required to make 25 ml of a 25 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=25 μM, V2=25 ml and V1 is the unknown:
  • Enter 10 into the Concentration (Start) box and choose the correct unit (mM)
  • Enter 25 into the Concentration (End) box and select the correct unit (mM)
  • Enter 25 into the Volume (End) box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 62.5 μL (0.1 ml) appears in the Volume (Start) box
g/mol

Molecular Weight Calculator allows you to calculate the molar mass and elemental composition of a compound, as detailed below:

Note: Chemical formula is case sensitive: C12H18N3O4  c12h18n3o4
Instructions to calculate molar mass (molecular weight) of a chemical compound:
  • To calculate molar mass of a chemical compound, please enter the chemical/molecular formula and click the “Calculate’ button.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
  • Molecular mass (or molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
  • Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
/

Reconstitution Calculator allows you to calculate the volume of solvent required to reconstitute your vial.

  • Enter the mass of the reagent and the desired reconstitution concentration as well as the correct units
  • Click the “Calculate” button
  • The answer appears in the Volume (to add to vial) box
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal to make allowance for loss during the experiment)
Step 2: Enter in vivo formulation (This is only a calculator, not the exact formulation for a specific product. Please contact us first if there is no in vivo formulation in the solubility section.)
+
+
+

Calculation results

Working concentration mg/mL;

Method for preparing DMSO stock solution mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation:Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.

(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
             (2) Be sure to add the solvent(s) in order.

Clinical Trial Information
Exparel for Total Shoulder Arthroplasty
CTID: NCT04364867
Phase: Phase 4    Status: Completed
Date: 2024-11-26
Efficacy of Preventive Ketamine on Postoperative Pain
CTID: NCT04908579
Phase: Phase 4    Status: Recruiting
Date: 2024-11-26
Transversus Abdominis Plane (TAP) Block Using Liposomal Bupivacaine in Metabolic and Bariatric Surgery Patients
CTID: NCT05537883
Phase: Phase 1    Status: Completed
Date: 2024-11-26
Postoperative Analgesia Between Paravertebral Block and Epidural Block in Esophageal Surgery
CTID: NCT06704698
Phase: N/A    Status: Recruiting
Date: 2024-11-26
Video-assisted Thoracoscopic Surgery - Exparel Study
CTID: NCT04864210
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-11-25
View More

Liposomal Bupivacaine Vs Bupivacaine with Dexmedetomidine in Erector Spinae Plane Blocks for Mastectomies
CTID: NCT06252662
Phase: Phase 4    Status: Recruiting
Date: 2024-11-19


Pecto-Intercostal Fascial Plane Block Study
CTID: NCT04928339
Phase: Phase 4    Status: Completed
Date: 2024-11-19
Peripheral Nerve Stimulation of Genicular Nerves Versus Conventional Therapy With Intra-articular Steroid Injection for Chronic Knee Pain: A Prospective, Randomized Pilot Study
CTID: NCT06004882
Phase: N/A    Status: Recruiting
Date: 2024-11-18
Effectiveness of Corticosteroid vs Ketorolac Shoulder Injections
CTID: NCT04895280
Phase: Phase 4    Status: Withdrawn
Date: 2024-11-15
Thoracic Paravertebral Block for Postoperative Pain Management After VATS
CTID: NCT06689358
Phase: N/A    Status: Completed
Date: 2024-11-14
Repeat or Single Quadratus Lumborum Block for the Reduction of Opioid Prescriptions After Surgery in Retroperitoneal Sarcoma Patients ('RESQU-SARC' Trial)
CTID: NCT04189783
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-11-13
Intravesical Bupivacaine on Post-Operative Ureteroscopy Pain
CTID: NCT06635889
Phase: Phase 2    Status: Not yet recruiting
Date: 2024-11-13
The PAIN (Pelvic Area Injection for Numbness) Study
CTID: NCT05972681
Phase: Phase 4    Status: Recruiting
Date: 2024-11-12
Efficacy of Liposomal Bupivacaine Post Septorhinoplasty
CTID: NCT05964868
Phase: Phase 3    Status: Enrolling by invitation
Date: 2024-11-12
Prophylactic Mirtazapine and Different Doses of Intrathecal Morphine in Preventing Nausea and Vomiting After Cesarean Section
CTID: NCT06681805
Phase: N/A    Status: Completed
Date: 2024-11-08
Anesthesia and Perioperative Neurocognitive Disorders in the Elderly Patients Undergoing Hip Fracture Surgery Platform Trial (ANDES Platform Trial)
CTID: NCT06452147
Phase: N/A    Status: Recruiting
Date: 2024-11-08
Effect of Adding Magnesium Sulphate As Adjuvant to Bupivacaine in Ultrasound Guided External Oblique Intercostal Plane Block in Upper Abdominal Cancer Surgery.to Assess the Total Postoperative Opioid Consumption in the First 24 H and Evaluate Post Operative VAS Score
CTID: NCT06677827
Phase: Phase 4    Status: Not yet recruiting
Date: 2024-11-07
Intraperitoneal Bupivacaine for Pelvic Organ Prolapse
CTID: NCT06120530
Phase: Phase 4    Status: Completed
Date: 2024-11-07
EOIB for Laparoscopic Cholecystectomy
CTID: NCT06656299
Phase: N/A    Status: Recruiting
Date: 2024-11-01
Transabdominal Plane (TAP) Blocks for Inguinal Hernia Repairs
CTID: NCT05672680
Phase: Phase 2/Phase 3    Status: Completed
Date: 2024-10-30
Evaluation of Pain Management After Surgery When Using Exparel in the Pediatric Population
CTID: NCT06559215
Phase: Phase 2    Status: Not yet recruiting
Date: 2024-10-30
Stellate Ganglion Block
CTID: NCT06271707
Phase: Phase 4    Status: Not yet recruiting
Date: 2024-10-30
Effect of Bupivacaine Liposomes or Bupivacaine for Femoral Triangle or Adductor Block on Analgesia After Total Knee Replacement
CTID: NCT06653621
Phase: Phase 4    Status: Not yet recruiting
Date: 2024-10-24
Study to Evaluate the Pharmacokinetics and Safety of EXPAREL for Postoperative Analgesia in Subjects Undergoing Cardiac Surgery
CTID: NCT06271265
Phase: Phase 1    Status: Recruiting
Date: 2024-10-24
Superficial Cervical Plexus Block and Quality of Recovery After Thyroidectomy
CTID: NCT06002152
Phase: Phase 2    Status: Recruiting
Date: 2024-10-24
Phase 3 Adductor Canal Block With EXPAREL in Subjects Undergoing Primary Unilateral Total Knee Arthroplasty
CTID: NCT05139030
Phase: Phase 3    Status: Completed
Date: 2024-10-24
Comparison of Infraclavicular Brachial Plexus Block and Local Anesthesia in Arteriovenous Fistula Surgeries and Their Effects on Tissue Oxygen Saturation
CTID: NCT06416111
Phase: N/A    Status: Completed
Date: 2024-10-17
Rectus Sheath Block for Analgesia After Gynecological Laparotomy
CTID: NCT06575699
Phase: Phase 4    Status: Recruiting
Date: 2024-10-17
Transvaginal Versus Fluoroscopy-guided Trans Gluteal Pudendal Nerve Block for Pudendal Neuralgia: a Prospective, Noninferiority, Randomized Controlled Trial
CTID: NCT06644261
PhaseEarly Phase 1    Status: Recruiting
Date: 2024-10-16
Liposomal Bupivacaine With or Without Hydromorphone for the Improvement of Pain Control After Laparotomy in Patients With Gynecological Malignancies
CTID: NCT04258631
Phase: Phase 4    Status: Completed
Date: 2024-10-16
Fascia Iliaca Compartment Block Versus Anterior Quadratus Lumborum Block
CTID: NCT04709211
Phase: N/A    Status: Completed
Date: 2024-10-09
Sphenopalatine Ganglion Block Study
CTID: NCT05707754
Phase: Phase 1    Status: Completed
Date: 2024-10-08
IV Methadone Vs EXPAREL Erector Spinae Plane Blockade in Pediatric Subjects Undergoing Idiopathic Scoliosis Correction
CTID: NCT05730920
Phase: Phase 4    Status: Completed
Date: 2024-10-04
Pain Control for Undergoing Costal Cartilage Harvesting
CTID: NCT05285566
Phase: Phase 4    Status: Recruiting
Date: 2024-10-02
Thoracic Epidural Analgesia vs Surgical Site Infiltration With Liposomal Bupivacaine Following Open Gynecologic Surgery
CTID: NCT04117074
Phase: Phase 3    Status: Recruiting
Date: 2024-10-02
Pectoral Nerve Blocks (PECs) for Cardiovascular Implantable Electronic Device Placement
CTID: NCT05283980
Phase: Phase 2/Phase 3    Status: Active, not recruiting
Date: 2024-10-01
Outcomes for Lumbar Decompressions With Use of Liposomal Bupivicaine
CTID: NCT04066296
Phase: Phase 2    Status: Recruiting
Date: 2024-10-01
EXPAREL IPSA Block in Knee Arthroplasty
CTID: NCT06619340
Phase: Phase 4    Status: Enrolling by invitation
Date: 2024-10-01
The Effect of Intraperitoneal Instillation of Bupivacaine on Postoperative Pain After Surgical Laparoscopy
CTID: NCT06616441
Phase: Phase 3    Status: Completed
Date: 2024-09-27
Efficacy and Safety of Liposomal Bupivacaine Injection for Paravertebral Nerve Block in the Treatment of Acute and Chronic Pain After Thoracoscopic Pneumonectomy: a Multicenter, Randomized, Double-blind, Controlled Clinical Trial
CTID: NCT06569953
Phase: Phase 4    Status: Recruiting
Date: 2024-09-26
Mepivacaine Versus Bupivacaine Onset Time in Ultrasound-guided Ankle Blocks
CTID: NCT05425979
Phase: Phase 4    Status: Enrolling by invitation
Date: 2024-09-19
A Novel Analgesia Technique for ACL Reconstruction
CTID: NCT03292926
Phase: Phase 4    Status: Completed
Date: 2024-09-19
Intrathecal Morphine vs. Intrathecal Morphine and Regional Anesthesia After Cesarean Section.
CTID: NCT06114121
Phase: Phase 4    Status: Withdrawn
Date: 2024-09-19
Utility of Liposomal Bupivacaine Transversus Abdominal Plane Block for Open Myomectomy
CTID: NCT04272086
Phase: Phase 4    Status: Recruiting
Date: 2024-09-19
Efficacy of Opioid-limiting Pain Management Protocol in Men Undergoing Urethroplasty
CTID: NCT03859024
Phase: Phase 4    Status: Completed
Date: 2024-09-19
Peripheral Nerve Injections for CRPS
CTID: NCT04744675
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-09-19
Comparing Intrathecal Morphine and Intraoperative Lidocaine Infusion to Epidural Anesthesia With Postoperative PCA for Patients Undergoing Exploratory Laparotomy
CTID: NCT05017246
Phase: Phase 2    Status: Terminated
Date: 2024-09-03
Exparel Versus Bupivacaine in Post-operative Pain Control
CTID: NCT06547255
Phase: Phase 4    Status: Recruiting
Date: 2024-09-03
Exparel v Dexamethasone in RCR
CTID: NCT06575010
Phase: Phase 4    Status: Enrolling by invitation
Date: 2024-08-28
Post-mastectomy Recovery: Comparing Preoperative PECS-II Blocks With Intraoperative Pectoral Blocks
CTID: NCT06574022
Phase: Phase 4    Status: Not yet recruiting
Date: 2024-08-27
Lignocaine vs Bupivacaine Infiltration for Postpartum Perineal Pain After Vaginal Delivery With Episiotomy in Primigravidae
CTID: NCT06568289
Phase: N/A    Status: Recruiting
Date: 2024-08-23
Pilot Study of Liposomal Bupivacaine Redosing in Patients Undergoing Major Gynecologic Procedures
CTID: NCT04849858
Phase: Phase 3    Status: Terminated
Date: 2024-08-23
EXPAREL or Lidocane as Local Anesthetic in Patients Undergoing Pleuroscopy With Pleural Biopsy and Indwelling Pleural Catheter Placement
CTID: NCT05044468
Phase: Phase 2    Status: Recruiting
Date: 2024-08-21
Comparison of Intraperitoneal Bupivacaine Alone or With Dexmedetomidine
CTID: NCT06560892
Phase: N/A    Status: Completed
Date: 2024-08-21
A Study of Bupivacaine Liposome Injection in Local Analgesia of Pediatric Patients
CTID: NCT06344091
Phase: Phase 4    Status: Recruiting
Date: 2024-08-21
Periarticular Injection Versus Popliteal Block
CTID: NCT04575688
Phase: Phase 4    Status: Enrolling by invitation
Date: 2024-08-21
Mepivacaine vs Bupivacaine Spinal Anesthesia for TKA
CTID: NCT06291727
Phase: Phase 4    Status: Recruiting
Date: 2024-08-20
Efficacy and Safety of Liposomal Bupivacaine Using Periarticular Injection in Total Knee Arthroplasty
CTID: NCT06557018
Phase: Phase 4    Status: Recruiting
Date: 2024-08-16
Erector Spinae Regional Anesthesia for Pain Control
CTID: NCT05794828
PhaseEarly Phase 1    Status: Recruiting
Date: 2024-08-09
Optimizing Recovery in Abdominoplasty
CTID: NCT04254692
Phase: Phase 4    Status: Terminated
Date: 2024-08-07
Pec Infiltration With Liposomal Bupivacaine for Breast Surgery
CTID: NCT03599635
Phase: Phase 4    Status: Completed
Date: 2024-08-06
Postoperative Analgesia With Liposomal Bupivacaine Versus Standard Bupivacaine Combined With Dexamethasone
CTID: NCT06173466
Phase: Phase 4    Status: Completed
Date: 2024-08-05
Thoracic Epidural Analgesia or Four-Quadrant Transversus Abdominus Plane Block in Reducing Pain in Patients Undergoing Liver Surgery
CTID: NCT03214510
Phase: Phase 3    Status: Recruiting
Date: 2024-08-02
A Study of Bupivacaine Liposome Injection in the Treatment of Pain After Thoracoscopic Surgery
CTID: NCT06529432
Phase: Phase 2    Status: Not yet recruiting
Date: 2024-07-31
Hypobaric L5-S1 Study
CTID: NCT06526156
Phase:    Status: Recruiting
Date: 2024-07-29
Bilateral Rhomboid Intercostal Block for Perioperative Analgesia in Patients Undergoing Bilateral Reduction Mammoplasty
CTID: NCT06225895
Phase: N/A    Status: Recruiting
Date: 2024-07-24
Effect of Prilocaine vs Bupivacaine on Hemodynamics in Spinal Anesthesia for Geriatric Patients
CTID: NCT06165679
Phase: Phase 3    Status: Recruiting
Date: 2024-07-23
Bilateral Recto-Intercostal Fascial Plane Block in Epigastric Hernia Repair
CTID: NCT06092073
Phase: N/A    Status: Recruiting
Date: 2024-07-23
Multimodal Orthognathic Study Comparing Use of Exparel With Standard of Care.
CTID: NCT06499181
PhaseEarly Phase 1    Status: Completed
Date: 2024-07-19
Dorsal Nerve Block and Caudal Block in Hypospedius Repair in Children
CTID: NCT06500286
Phase: Phase 1    Status: Not yet recruiting
Date: 2024-07-15
Liposomal Bupivacaine Use in Alveolar Bone Graft Patients
CTID: NCT06284434
Phase: Phase 3    Status: Recruiting
Date: 2024-07-03
Local Anesthetic for Plateau Fractures
CTID: NCT06474949
Phase: Phase 4    Status: Not yet recruiting
Date: 2024-06-26
Postoperative Pain Control in AIS Using Liposomal Bupivacaine vs. 0.25% Bupivacaine With Epinephrine
CTID: NCT06471348
Phase: N/A    Status: Not yet recruiting
Date: 2024-06-24
Exparel vs Block for ACL Reconstruction
CTID: NCT06006624
Phase: Phase 4    Status: Enrolling by invitation
Date: 2024-06-21
Erector Spinae Plane Block With Bupivacaine for Medical Thoracoscopy
CTID: NCT06313632
Phase: Phase 3    Status: Recruiting
Date: 2024-06-18
Supraclavicular Bupivacaine Vs. Supraclavicular Liposomal Bupivacaine for Distal Radius Fracture Repair
CTID: NCT06179004
Phase: Phase 3    Status: Recruiting
Date: 2024-06-17
Exparel Injection for Postoperative Orbital Pain
CTID: NCT02381353
Phase: Phase 4    Status: Recruiting
Date: 2024-06-13
Analgesic Requirement for Post-Operative Pain Control in TLIP Interbody Fusion
CTID: NCT06350981
Phase: Phase 2/Phase 3    Status: Enrolling by invitation
Date: 2024-06-13
Development of Effective, Opioid Sparing Techniques for Peri-operative Pain Management of Transgender Patients Undergoing Gender Affirming Surgeries
CTID: NCT04979338
Phase: Phase 3    Status: Recruiting
Date: 2024-06-12
Phase 1, Dose Escalation Study to Evaluate of Safety, Pharmacokinetics and Pharmacodynamics of Liposomal Bupivacaine 13.3 Administered Via a Single Intrathecal Injection to Healthy Volunteers
CTID: NCT05456490
Phase: Phase 1    Status: Recruiting
Date: 2024-06-05
Role of Ultrasound Guide Greater Occipital Nerve Block at Second Cervical Vertebra in Migraine Headache Prophylaxis
CTID: NCT06432127
Phase: Phase 4    Status: Not yet recruiting
Date: 2024-05-29
Erector Spinae Block for Spine Surgery
CTID: NCT05417113
Phase: Phase 4    Status: Terminated
Date: 2024-05-29
Liposomal Bupivacaine vs Ropivacaine for TAPBs
CTID: NCT06430112
Phase: Phase 3    Status: Recruiting
Date: 2024-05-28
Liposomal Bupivacaine Versus Plain Bupivacaine After Intercostal Injections For Pain Management After Thoracoscopy
CTID: NCT03737292
Phase: Phase 4    Status: Recruiting
Date: 2024-05-24
Erector Spinae Plane Block Versus Conventional Analgesia in Complex Spine Surgery
CTID: NCT04156581
Phase: Phase 4    Status: Completed
Date: 2024-05-24
Exparel as a Nerve Block for Severe Hand Pain
CTID: NCT02374320
Phase: Phase 2/Phase 3    Status: Terminated
Date: 2024-05-21
A Study of Stellate Ganglion Block for Prevention of Atrial Fibrillation
CTID: NCT05357690
Phase: Phase 2/Phase 3    Status: Recruiting
Date: 2024-05-16
Liposomal Bupivacaine in Rotator Cuff Repair
CTID: NCT03738696
Phase: Phase 4    Status: Completed
Date: 2024-05-16
A Study of Loco-Regional Liposomal Bupivacaine Injection
CTID: NCT05992896
Phase: Phase 4    Status: Recruiting
Date: 2024-05-16
Rectus Sheath Block With Liposomal Bupivacaine Versus Thoracic Epidural Analgesia for Pain Control Following Pancreatoduodenectomy
CTID: NCT06411795
Phase: Phase 2    Status: Recruiting
Date: 2024-05-13
Effect of Addition of Steroids on Duration of Analgesia
CTID: NCT04126824
PhaseEarly Phase 1    Status: Active, not recruiting
Date: 2024-05-13
Short Title: Standard vs. Lower Pressure Pneumoperitoneum
CTID: NCT06338865
Phase: N/A    Status: Recruiting
Date: 2024-05-10
Comparison of the Ultrasound-guided Paravertebral Nerve Block With Liposomal Bupivacaine Versus Ropivacaine for Post-Surgical Pain After Video-Assisted Thoracoscopic Surgery
CTID: NCT06405724
Phase: Phase 3    Status: Not yet recruiting
Date: 2024-05-08
Liposomal Bupivacaine Single-Injection Interscalene Block vs. Continuous Interscalene Block for Primary Total Shoulder Arthroplasty
CTID: NCT05005260
Phase: Phase 4    Status: Completed
Date: 2024-05-07
Comparison of Analgesic Efficacy Between of Interscalene Block With Liposomal Bupivacaine With Bupivacaine and Dexamethasone
CTID: NCT03969875
Phase:    Status: Completed
Date: 2024-05-07
Zynrelef vs Exparel: The Battle of Postoperative Pain Control After Robotic Sleeve Gastrectomy
CTID: NCT06349772
PhaseEarly Phase 1    Status: Not yet recruiting
Date: 2024-05-07
Genicular and Anterior Femoral Cutaneous Nerve Blocks for Total Knee Arthroplasty
CTID: NCT05980546
Phase: Phase 4    Status: Recruiting
Date: 2024-05-01
Liposomal Bupivacaine Versus Lidocaine for Skin Graft Donor Site Pain
CTID: NCT03854344
Phase: Phase 4    Status: Recruiting
Date: 2024-05-01
Minimal Opioid Use After Total Hip Replacement (THR)
CTID: NCT03090152
Phase: Phase 4    Status: Completed
Date: 2024-05-01
Laparoscopic vs Ultrasound-Guided Transversus Abdominis Plane Block vs Laparoscopic Intraperitoneal Instillation of Local Anesthetic in Pediatrics
CTID: NCT06098105
Phase: N/A    Status: Completed
Date: 2024-04-25
Liposomal Bupivacaine for Postoperative Pain Control in Urologic Procedures
CTID: NCT02805504
Phase: Phase 4    Status: Completed
Date: 2024-04-24
Dexametomedine Versus Ketamine as an Adjuvant in Erector Spinae Block for Perioperative Thoracotomy Pain Control
CTID: NCT05552391
Phase: Phase 4    Status: Completed
Date: 2024-04-18
A Study of Liposomal Bupivacaine Versus 0.25% Bupivacaine Hydrochloride Post Breast Reduction
CTID: NCT05891613
Phase: Phase 4    Status: Recruiting
Date: 2024-04-17
Quality Of Recovery After Pericapsular Nerve Group (PENG) Block For Hip Hemiarthroplasty Under Spinal Anesthesia
CTID: NCT06369948
Phase: N/A    Status: Recruiting
Date: 2024-04-17
Clinical Trial of Endoscopically Guided Injection of Exparel (Bupivacaine) for the Treatment of Craniofacial Pain
CTID: NCT04930887
Phase: Phase 2    Status: Recruiting
Date: 2024-04-17
Interscalene Single Shot With Plain Bupivacaine Versus Liposomal Bupivacaine for Arthroscopic Shoulder Surgery
CTID: NCT03638960
Phase: Phase 4    Status: Completed
Date: 2024-04-15
Effects of Stellate Ganglion Block in Post-traumatic Stress Disorder
CTID: NCT05391971
Phase: Phase 4    Status: Recruiting
Date: 2024-04-11
Liposomal Bupivacaine + Bupivacaine vs. Bupivacaine Alone on Opioid Use After Elective c/Section
CTID: NCT04232306
Phase: Phase 4    Status: Withdrawn
Date: 2024-04-10
Infraclavicular Brachial Plexus Block With Bupivacaine Alone or With Both Dexmedetomidine and Dexamethasone
CTID: NCT06356415
Phase: N/A    Status: Not yet recruiting
Date: 2024-04-10
Comparison of Analgesic Efficacy in Video-Assisted Thoracoscopic Surgery Patients
CTID: NCT06352398
Phase: N/A    Status: Completed
Date: 2024-04-08
Ultrasound Guided Femoral Nerve Block
CTID: NCT02381717
Phase: N/A    Status: Recruiting
Date: 2024-04-03
Efficacy and Safety of Dexmedetomidine to Bupivacaine in Supraclavicular Brachial Plexus Block
CTID: NCT06020781
Phase: N/A    Status: Completed
Date: 2024-04-02
Dexmedetomidine and Ketamine as an Adjuvant in External Oblique Intercostal Plane Block for Post Thoracotomy Pain
CTID: NCT06331182
Phase: N/A    Status: Recruiting
Date: 2024-03-27
Effect of Stellate Ganglion Block on ME/CFS
CTID: NCT05664711
Phase: Phase 1    Status: Active, not recruiting
Date: 2024-03-21
Steroids in Occipital Nerve Block for Treatment of Headache
CTID: NCT05732532
Phase: Phase 4    Status: Recruiting
Date: 2024-03-21
H
The effect of subpectineal obturator nerve block on opioid consumption and pain after hip arthroscopy
CTID: null
Phase: Phase 4    Status: Completed
Date: 2022-03-08
Pain after thoracoscopic lung surgery – the effect of intercostal nerve blockades with standard bupivacaine and liposomal bupivacaine – a randomised controlled feasibility trial
CTID: null
Phase: Phase 2    Status: Prematurely Ended
Date: 2021-09-08
Knee osteoarthritis Injection Therapy (KNiT) trial
CTID: null
Phase: Phase 4    Status: Prematurely Ended
Date: 2021-05-31
The effect of iliopsoas plane block on opioid consumption and pain after hip arthroscopy
CTID: null
Phase: Phase 4    Status: Completed
Date: 2021-03-22
The effect of the popliteal plexus block on postoperative opioid consumption, pain, muscle strength and mobilization after total knee arthroplasty
CTID: null
Phase: Phase 4    Status: Completed
Date: 2021-03-12
Optimal postoperative Pain management After Lung surgery (OPtriAL): multi-centre randomised trial
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2021-02-03
Does perineural dexamethasone increase the duration of an ulnar nerve block when controlling for systemic effects? A randomised, blinded, placebo-controlled, paired, non-inferiority trial in healthy volunteers
CTID: null
Phase: Phase 2    Status: Completed
Date: 2020-12-21
Analgesic efficacy of repetitive nerve blockade after major ankle and hindfoot surgery - A feasibility study
CTID: null
Phase: Phase 4    Status: Prematurely Ended
Date: 2020-08-18
a Randomized controlled trial for epidural Analgesia for Pain relief after lumbar Interlaminar Decompressive spine surgery - RAPID
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2020-06-15
The effect of subpectineal obturator nerve block on opioid consumption and pain after hip arthroscopy
CTID: null
Phase: Phase 4    Status: Completed
Date: 2020-05-12
Analgesic efficacy of repetitive nerve blockade after major ankle and hindfoot surgery - A feasibility study
CTID: null
Phase: Phase 4    Status: Prematurely Ended
Date: 2019-06-14
Hyperbaric Bupivacaine Versus Hyperbaric Prilocaine 2% for Cesarean Section Under Spinal Anesthesia: a Randomised and Controlled Clinical Trial
CTID: null
Phase: Phase 3    Status: Prematurely Ended
Date: 2018-01-11
Comparison of motor blockade duration in the context of scheduled caesarean section with spinal anaesthesia : hyperbaric Prilocaïne versus hyperbaric Bupivacaïne.
CTID: null
Phase: Phase 2    Status: Ongoing
Date: 2017-12-11
The effects of sufentanil or morphine added to hyperbaric bupivacaine in
CTID: null
Phase: Phase 4    Status: Completed
Date: 2017-11-07
Onset and duration of Forearm nerve blockade performed with a single distal injection versus sequential injections at distal and proximal locations alongside the nerves: a blinded randomized controlled trial.
CTID: null
Phase: Phase 4    Status: Completed
Date: 2017-10-25
SPAARK: Study of Peri-Articular Anaesthetic for Replacement of the Knee.
CTID: null
Phase: Phase 3    Status: GB - no longer in EU/EEA
Date: 2017-09-18
A Phase 3, Randomized, Double-Blind, Saline Placebo- and Active-Controlled, Multicenter Study of HTX-011 via Local Administration for Postoperative Analgesia and Decreased Opioid Use Following Unilateral Open Inguinal Herniorrhaphy
CTID: null
Phase: Phase 3    Status: Completed
Date: 2017-09-15
A prospective, randomized, parallel comparative clinical trial comparing the safety of perioperative analgesic efficacy of the PEC II block with BRILMA in breast surgery.Version 4, of May 16, 2017
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2017-06-08
The effect of popliteal plexus block on pain after total knee replacement
CTID: null
Phase: Phase 4    Status: Completed
Date: 2017-06-01
Postoperative analgesia after elective hip surgery - effect of obturator nerve blockade
CTID: null
Phase: Phase 4    Status: Completed
Date: 2017-05-24
Regional anaesthesia of the cutaneus nerves of the hip -
CTID: null
Phase: Phase 4    Status: Completed
Date: 2016-12-19
Randomized controlled prospective study on the injection of corticoids for the treatment of acute sprains of the proximal interphalangeal joints of the fingers (thumb excluded).
CTID: null
Phase: Phase 2    Status: Completed
Date: 2016-12-08
The utility of liposomal bupivacaine for anesthesia and analgesia in patients treated with collagenase for the release of Dupuytren’s contracture: A randomized controlled trial.
CTID: null
Phase: Phase 3    Status: Completed
Date: 2016-11-17
Quality of analgesia after ultrasound-guided specific blocks of the distal tibial and deep peroneal nerves with 15 mL of a 50:50 mixture bupivacaine 0.5% and liposome bupivacaine (Exparel®) )1.3% vs. 15mL of bupivacaine 0.5% and vs. general anesthesia after hallux valgus surgery.
CTID: null
Phase: Phase 3    Status: Ongoing
Date: 2016-11-14
The lateral femoral cutaneous nerve – description of the sensory territory and a novel ultrasound guided nerve block technique
CTID: null
Phase: Phase 4    Status: Completed
Date: 2016-10-14
The haemodynamic effects of spinal anaesthesia with versus without sufentanil added to bupivacaine heavy
CTID: null
Phase: Phase 4    Status: Ongoing
Date: 2016-09-20
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Brachial Plexus Block with EXPAREL for Postsurgical Analgesia in Subjects Undergoing Total Shoulder Arthroplasty or Rotator Cuff Repair
CTID: null
Phase: Phase 3    Status: Completed
Date: 2016-06-10
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Femoral Nerve Block with EXPAREL for Postsurgical Analgesia in Subjects Undergoing Total Knee Arthroplasty
CTID: null
Phase: Phase 3    Status: Completed
Date: 2016-06-10
Surgical anesthesia for elective hip surgery - hemodynamic effect of lumbosacral plexus blockade compared to continuous spinal anesthesia
CTID: null
Phase: Phase 4    Status: Prematurely Ended
Date: 2016-03-18
Gluteus medius fascia plane block - Validating a new nerve block technique
CTID: null
Phase: Phase 4    Status: Prematurely Ended
Date: 2015-10-12
Pharmacokinetic Profile of Liposome Bupivacaine (Exparel®) after Perineural Admission in the Interscalene Groove for Primary Total Shoulder Arthroplasty.
CTID: null
Phase: Phase 1, Phase 2    Status: Ongoing
Date: 2015-08-27
Preoperative analgesic affect of combined obturator and femoral nerve block compared to femoral nerve block alone, in patients with hip fracture.
CTID: null
Phase: Phase 4    Status: Prematurely Ended
Date: 2015-07-30
Tendinopathy treatment effects and mechanisms 1 (TEAM 1): A randomised clinical trial of eccentric loading, high volume injection and shock wave therapy for Achilles tendinopathy.
CTID: null
Phase: Phase 4    Status: GB - no longer in EU/EEA
Date: 2015-07-28
CLINICAL TRIAL TO EVALUATE THE EFFICACY AND THE SECURITY OF DEXAMETASONE+BUPIBACAINE+ARTICAINE+EPINEFRINE “VERSUS” ARTICAINE+EPINEFRINE IN THE POSTQUIRURGICAL PAIN OF THIRD MOLAR SURGERY
CTID: null
Phase: Phase 3    Status: Completed
Date: 2015-04-23
Protracted mixture of local anaesthetics for major foot and ankle surgery. A randomized double-blind, controlled study comparing Bupivacaine-epinephrine 0.5% and Bupivacaine-epinepherine 0.5% plus dexamethasone
CTID: null
Phase: Phase 4    Status: Completed
Date: 2015-04-08
Infiltration of bupivacaine and triamcinolone at Milligan-Morgan hemorrhoidectomy surgical site to manage postoperative p e.querySelector("font strong").innerText = 'View More' } else if(up_display === 'none' || up_display === '') { icon_angle_down.style.display = 'none'; icon_a

Contact Us